HIV Vaccine Market Opportunity & Clinical Pipeline Analysis

Description: Ever since HIV was identified as the cause for AIDS 30 years ago, the HIV virus has become one of the greatest challenges of public health facing all countries of the world. According to UNAIDS, death due to AIDS was estimated to close to 1.6 million in 2012. There were 2.3 million new HIV infections, and about 35.3 million people currently living with HIV.

Given the pace at which the HIV virus is spreading, it is most likely that AIDS would take more lives than any other infectious disease in the future years to come. Inspite of well-expanded programs of prevention and treatment which are currently enabling the stakeholders to address the illness and death associated with HIV and AIDS, the HIV vaccines is considered to be the best solution to end this disease successfully.

HIV/AIDS has become of the leading infectious disease which is taking a huge death toll across the globe, even surpassing TB and malaria. Irrespective of whether the country is developed or developing, the disease is increasingly becoming prevalent, though with serious impact in the developing countries.

It has been observed that almost nine out of every ten HIV infections are being diagnosed in the developing countries, and two-thirds are in Sub-Saharan Africa. India currently has close to 4 million infected people, which is the largest number of infected persons of any country in the world. Despite of the combating efforts, the Asian and other developing regions are increasingly feeling the heat as HIV continues to spread at a significant rate.

In recent years there have been significant breakthroughs achieved in terms of prevention and treatment of HIV/AIDS. The future is also likely to continue to witness similar technological and medical success in terms of new drugs and an efficient vaccine, with the help of adequate funding.

Certain developments like a new treatment to reduce transmissibility in drug users and new efforts to strengthen the immune system have the potential to develop further and provide better healthcare services to the patients in the future.

It is expected that in the next 5-8 years, the pharmaceutical companies would focus more on the development of a successful efficient vaccine to control the spread of this disease. The allocation of resources should necessarily reflect ongoing, strategic prioritization of candidates in the pipeline. With the progress of trials and accumulation of information on the safety and efficacy of new products, there is an urgent demand for strategizing the product pipelines and the prioritization of the decisions.

There needs to be complete scrutiny of every single technological area of HIV prevention R&D so as to reflect the best methods of channelizing the funds which are limited in nature. The funds need to be specifically directed towards only those products and approaches which have a high probability of succeeding, instead of those which are less promising.

HIV Vaccine Market Opportunity & Clinical Pipeline Analysis Report Highlights:

- Introduction to HIV Vaccine & Mechanism
- Global HIV Incidence Scenario
- R&D Funding Scenario for HIV Vaccine
- FDA Regulatory Framework
- HIV Vaccine Clinical Trial by Phase & Country
- HIV Vaccines in Development Phase: More Than 100
- Most HIV Vaccines in Preclinical Phase: More Than 50
- Discontinued & Suspended HIV Vaccines Profiles

Contents: 1. Introduction to HIV Vaccine & Mechanism
1.1 Introduction
1.2 The Mechanics of HIV Vaccines
2. HIV Vaccine: Prevention & Cure
   2.1 Prevention
   2.2 Cure & Access to Antiretroviral Therapy

3. Why Need For HIV Vaccines?

4. Global HIV Vaccine Market Outlook
   4.1 HIV Incidence Scenario
   4.2 Market Overview
   4.3 Clinical Trial Analysis

5. Research & Development Funding Scenario for HIV Vaccine

6. HIV Vaccine Market Dynamics
   6.1 Favorable Market Drivers
   6.2 Challenges to be Resolved
   6.3 Future Growth Opportunity

7. FDA Regulatory Framework for Development of HIV Vaccine
   7.1 Development of Preventive HIV Vaccines for Use in Paediatric Populations
   7.2 Guidance for Submitting HIV Resistance Data
   7.3 HIV Resistance Testing in Antiretroviral Drug Development

8. HIV Vaccine Clinical Trial by Phase & Country
   8.1 Research
   8.2 Preclinical
   8.3 Clinical
   8.4 Phase I
   8.5 Phase I/II
   8.6 Phase II
   8.7 Phase III

9. Discontinued & Suspended HIV Vaccine Clinical Trial by Phase & Country
   9.1 No Development Reported
   9.2 Discontinued
   9.3 Suspended

10. Competitive Landscape
    10.1 Antigen Express
    10.2 Bionor Pharma
    10.3 FIT Biotech
    10.4 GeoVax
    10.5 GenVec
    10.6 Glaxo Smithkline
    10.7 Immune Response BioPharma
    10.8 Inovio Pharmaceuticals
    10.9 Novartis
    10.10 Sanofi Pasteur

List Of Tables and Figures:

Table 5-1: HIV Vaccines Funding by Sector (US$ Million), 2006-2012
Table 6-1: HIV Vaccine Impact Analysis on Incidence & Deaths

Figure 1-1: Vaccine Research Process
Figure 4-1: People Living With HIV Infection (Million), 2009-2014
Figure 4-2: New Incidence of HIV Infection (Million), 2009-2012
Figure 4-3: People Living With HIV Infection by Region (%), 2012
Figure 4-4: People Accessing Treatment for HIV Infection (Million), 2009-2012
Figure 4-5: Global HIV/AIDS Therapeutics Market (US$ Billion), 2012-2018
Figure 4-6: HIV Vaccines in Clinical Trial by Phase (%), 2014
Figure 4-7: Number of HIV Vaccines in Clinical Trial by Phase, 2014
Figure 4-8: Suspended & Discontinued HIV Vaccines in Clinical Trial (%), 2014
Figure 4-9: Number of Suspended & Discontinued HIV Vaccines in Clinical Trial, 2014
Figure 4-10: Discontinued HIV Vaccines in Clinical Trial by Phase (%), 2014
Figure 4-11: Number of Discontinued HIV Vaccines in Clinical Trial by Phase, 2014
Figure 4-12: HIV Vaccines in Clinical Trial by Phase Where No Development Reported (%), 2014
Figure 4-13: Number of HIV Vaccines in Clinical Trial by Phase Where No Development Reported, 2014
Figure 5-1: Global HIV Vaccines R&D Funding (US$ Million), 2005–2012
Figure 5-2: Global HIV Vaccines R&D Funding Breakup (%), 2012
Figure 5-3: Philanthropic Sector Spending on HIV Vaccines by Clinical Research Phase (%), 2012

Ordering:

Order Online - http://www.researchandmarkets.com/reports/2771349/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: HIV Vaccine Market Opportunity & Clinical Pipeline Analysis
Web Address: http://www.researchandmarkets.com/reports/2771349/
Office Code: SCBR6S2L

Product Formats
Please select the product formats and quantity you require:

- **Quantity**
  - Hard Copy: [ ] USD 2500 + USD 58 Shipping/Handling
  - CD-ROM: [ ] USD 2200 + USD 58 Shipping/Handling
  - Electronic (PDF) - Single User: [ ] USD 2000
  - Electronic (PDF) - Enterprisewide: [ ] USD 3600

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

- **Title:** [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
- **First Name:** ____________________________
- **Last Name:** ____________________________
- **Email Address:** *
  _______________________________________
- **Job Title:** ____________________________
- **Organisation:** _________________________
- **Address:** _____________________________
- **City:** ________________________________
- **Postal / Zip Code:** ____________________
- **Country:** _____________________________
- **Phone Number:** _______________________
- **Fax Number:** _________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: _______________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World